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A b s t r a c t
Background: The importance of the role of monocytes in coronary artery disease (CAD) is well documented. An increased 
number of circulating monocytes is associated with higher incidence of CAD. Both environmental and genetic factors influence 
monocytosis. The latter have been extensively studied since the development of high-throughput genome-wide association 
studies. Several associations between polymorphisms and monocytosis were found among healthy individuals; the first example 
was rs7023923. The magnitude of the association of studied polymorphisms with the trait of interest is often confounded by 
environmental factors and may therefore differ between patient and healthy populations. It is very important to determine 
the magnitude of the association among patients to predict outcome of the disease, e.g. myocardial infarction. 
Aim: To determine whether the magnitude of association of rs7023923 with monocytosis, previously reported among healthy 
volunteers, is similar in patients in whom diagnosis of CAD was determined during elective coronarography. 
Methods and results: Leucocytosis and neutrophilocytosis were higher among patients with CAD, while thrombocytosis was 
lower. Monocyte count did not differ among the studied groups (p = 0.25). We confirmed the association of rs7023923 with 
monocytosis among healthy blood donors (p = 0.0156) but not among patients admitted for elective coronarography (p = 0.61). 
Inclusion of the age and sex of patients in the statistical model did not modify the results.
Conclusions: Our data suggest that translation of the results of genetic association with the studied traits from healthy to pa-
tient population should be implemented with caution. It is possible that numerous environmental factors, which discriminate 
healthy volunteers from CAD patients, confound the magnitude of genetic associations and make interpretation of the data 
in patients less clear.
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INTRODUCTION
Monocytes are a class of agranulocytes, which belong to the 
mononuclear phagocyte system and constitute 8–12% of all 
leukocytes. They develop from the joint myeloid progenitor 
cell in bone marrow. Mononuclear phagocytes play essential 
roles in the development of inflammation and host defence. 
Upon maturation, monocytes circulate freely in blood vessels 
for several days, but eventually infiltrate peripheral tissues, 
where they differentiate irreversibly to either macrophages or 
dendritic cells [1]. Monocytes participate in acute inflamma-
tion (e.g. in phagocytosis of pathogens and killing of infected 
host cells), but also in chronic diseases, in which cytokines are 
produced in response to antigen presentation [2]. Monocyte 
count is associated with chronic diseases, e.g. atherosclerosis 
[3], stroke [4], and peripheral arterial disease [5]. The factors 
that regulate the monocyte count remain partly unknown.
Clinical studies have demonstrated that monocytes play 
a key role in atherosclerosis [6, 7], myocardial infarction (MI) [8], 
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and healing after MI [9]. Monocytes are attracted to the coro-
nary artery wall, where they differentiate to macrophages, 
become loaded with lipids, and remain trapped there. At this 
point they present as foam cells and their presence contrib-
utes to the growth of atherosclerotic plaque, while cytokines 
produced by monocytes/macrophages may contribute to 
plaque instability and rupture, with clinical consequences of 
unstable angina or MI [10]. 
Basal monocyte count is related to various environmental 
factors, e.g. age, sex, and ethnicity [11–13]. Changes in circu-
lating monocyte count can occur rapidly, e.g. hours after infec-
tion, drug administration, tissue injury, and surgical stress [14]. 
However, monocyte count changes may also last for a long 
time, e.g. due to exercise therapy [15] or inflammatory bowel 
disease [16]. In contrast to environmental factors, relatively 
little is known about genetic factors that control monocyte 
count. In 2009, researchers from Queensland Institute of 
Medical Research in Australia demonstrated the influence 
of the single nucleotide polymorphism (SNP) rs7023923 on 
monocyte count in healthy volunteers [17]. This SNP is 
situated in an intergenic region of chromosome 9q31, near 
lysophosphatidic acid receptor 1 gene locus and is responsible 
for 1.5% of the variation in monocyte counts. The integral 
membrane protein encoded by this gene is a lysophosphatidic 
acid receptor (LPAR1), a member of the G protein-coupled 
receptor superfamily, which mediates diverse biological func-
tions, including proliferation, platelet aggregation, smooth 
muscle contraction, and chemotaxis [18]. 
Polymorphisms in the following loci were associated with 
monocyte count in Japanese subjects: rs12988934 in the 
ITGA4 locus, rs3095254 in the MHC region, rs10956483 in the 
MLZE locus, rs10147992 in the STXBP6 locus, and rs9373124 in 
the HBS1L-MYB locus [19]. In the African American popula-
tion, several polymorphisms in the Duffy antigen/receptor 
chemokine gene locus were associated both with total 
leukocyte and monocyte counts [20]. Both in the European 
and in mixed ancestry samples, novel associations were 
identified in the interferon regulatory factor 8 (IRF8) gene, 
chemokine-binding protein 2 (CCBP2) gene, and in a region 
of replication found in ribophorin I (RPN1) gene, while pre-
viously reported associations near ITGA4 and LPAR1 were 
confirmed [21]. The CCBP2 and RPN1 region is a site of 
binding GATA2 transcription factor, previously associated with 
coronary artery disease (CAD) [22].
Genotyping of polymorphisms, which regulate mono-
cyte count, may help predict risk of deadly complications of 
CAD, such as MI. However, it is important to know whether 
the associations between the polymorphisms and monocyte 
count, readily detectable in healthy subjects, can be repli-
cated in patients under the influence of classical risk factors 
for atherothrombosis, such as our patients, who were waiting 
for a coronary artery angiography procedure and were finally 
diagnosed with CAD. It is possible that environmental factors 
associated with monocyte count dwarf effects of studied 
polymorphisms, or even different polymorphisms, become 
important for monocyte count, due to their interaction 
with environment.
The goal of our study was to replicate the initial observa-
tion of association of polymorphism rs7023923 with mono-
cyte count in a Polish population of healthy blood donors 
and to verify whether the association of the same magnitude 
holds true in patients with CAD, confirmed during elective 
coronary angiography.
METHODS
Genotyping was performed in two groups: blood donors 
from south-east Poland (69 genotyped persons) and patients 
with CAD, confirmed during elective coronary angiography, 
in the Cardiology Department of John Paul II Hospital in 
Krakow (26 genotyped patients). Complete blood count, 
clinical characteristics, age, and sex of patients were obtained 
from hospital charts. All patients provided written informed 
consent. The experimental protocol was approved by the 
Bioethics Committee of the Jagiellonian University. Leukocytes 
were isolated from anticoagulated venous blood samples 
by centrifugation. Their DNA was isolated with TRIzol (Life 
Technologies), according to the manufacturer’s protocol. DNA 
was amplified by polymerase chain reaction (PCR), using 
primers complementary to the sequence, surrounding the 
studied polymorphism. 
Sequences of primers were the following: forward primer 
5’-GAATGTTTTTGACGATTTGGAA and reverse primer 5’-AA-
GTAGCTGCTAGACTGGCCTTA. The PCR conditions were the 
following: initial denaturation at 94°C for 5 min, followed by 
40 cycles of denaturation (94°C for 30 s), primer annealing 
(58°C for 45 s) and elongation (72°C for 45 s), ending with 
storage at 4°C until further analysis. Platinum Hot Start Poly-
merase (Life Technologies) was used for amplification. 
Digestion of the PCR product with FatI enzyme (Fer-
mentas), selected based on RestrictionMapper analysis, was 
performed according to the manufacturer’s protocol during 
14 h, at a temperature of 55°C, followed by 20 min at 65°C 
to inactivate the enzyme. Digestion products were separated 
by agarose gel electrophoresis with the addition of ethidium 
bromide. Genotypes were inferred after UV light transillumi-
nation of the gel. 
Primers were designed to be complementary to the 
non-repetitive DNA in this locus to avoid nonspecific PCR 
products. The result of the reaction was a product 173 bp 
long. FatI is potentially capable of cutting this product into two 
fragments, 141 bp and 32 bp long. Since the short fragment 
is difficult to visualise on the agarose gel and can be easily 
misinterpreted in the presence of primer band, we based the 
results on the identification of large fragments. Use of restric-
tion enzyme resulted in our samples in one of three possible 
patterns visible on the gel: a single 173 bp band in the case 
www.kardiologiapolska.pl
Polymorphism rs7023923 and monocyte count in blood donors and CAD patients
447
of no-cut homozygotes, two bands of 173 bp and 141 bp in 
the case of single allele cut heterozygotes, and a single band 
of 141 bp in the case of double allele cut homozygotes. An 
example of gel image interpretation is shown in Figure 1.
Statistical analysis
Wilcoxon test was used to compare counts of morphotic 
elements between the studied groups. Non-parametric 
Kruskal-Wallis test was used to evaluate the association of the 
genotypes with blood count of morphotic elements. Linear 
regression was used to account for the age and sex of the 
patients. Analysis was performed with SAS v. 9.3 (Cary, USA). 
P values less than 0.05 were considered statistically significant. 
Bonferroni correction for multiple testing was applied.
RESULTS
Distribution of sexes was similar in both studied groups: 
85.3% of males among blood donors, compared to 78.6% 
among patients subjected to coronary angiography (p = 0.53). 
Not surprisingly, blood donors were significantly younger 
than patients suspected of CAD: 34.0 ± 10.0 compared to 
57.3 ± 12.0 years of age (p < 0.0001).
Complete blood count parameters were compared 
between the two studied groups. The results are presented 
in Table 1.
The data show that patients admitted for elective an-
gioplasty have significantly higher leukocyte and neutrophil 
counts, but also significantly lower platelet count, compared 
to healthy blood donors. The erythrocyte, lymphocyte, and 
monocyte counts were not different between the studied 
groups. The clinical characteristics of the patients admitted 
for coronary angiography are presented in Table 2.
The distribution of genotypes was the following: in the 
healthy donor group CC (n = 33; 47.8%), CT (n = 16; 23.2%), 
and TT (n = 20; 29.0%); and in the group of patients with 
angiography CC (n = 12; 46.2%), CT (n = 8; 30.8%), and TT 
(n = 6; 23.1%). Therefore, the distribution of alleles in the 
healthy donor group was as follows: C (n = 82; 59.4%) and 
Figure 1. Results of restriction enzyme digestion of the polymerase chain reaction product: a) lanes 1, 7–8 (product 141 bp,  
double cut homozygotes); b) lanes 2, 4–6, 10 (products 173 bp and 141 bp, single cut heterozygotes); c) lanes 3 and 11  
(product 173 bp, no cut homozygotes; d) lane 9 — too weak product, required repeated analysis; e) lane 12 — DNA marker
Table 1. Comparison of morphotic element counts in blood 
of healthy blood donors and coronary artery disease suspects, 
admitted for elective angiography






Erythrocytes 4.95 ± 0.47 4.88 ± 0.27 0.52
Leukocytes 6.45 ± 1.24 8.54 ± 2.53 0.0003
Platelets 269.07 ± 56.10 212.64 ± 48.07 0.0011
Neutrophils 3.55 ± 1.05 5.73 ± 2.40 < 0.0001
Lymphocytes 2.10 ± 0.54 3.24 ± 3.96 0.24
Monocytes 0.50 ± 0.18 0.55 ± 0.16 0.25
Mean ± standard deviation values. Erythrocytes (mln/μL), other (thou-
sand/μL). Wilcoxon test p values, uncorrected for multiple testing, are 
shown. P values for leukocyte, neutrophil, and platelet count remain 
significant after Bonferroni correction.
Table 2. Clinical characteristics of patients subjected to elective 
coronary angioplasty (n = 26)
Variable Value
Final diagnosis of coronary artery disease 100%









Diabetes mellitus, type 2 32.1%




C-reactive protein [mg/L] 3.81 ± 3.0
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T (n = 56; 40.6%), and among patients with angiography: 
C (n = 32; 61.5%) and T (n = 20; 38.5%).
The association of polymorphism rs7023923 with count 
of blood morphotic elements in healthy blood doors is sum-
marised in Table 3.
The data show that polymorphism rs7023923 is associ-
ated with monocyte count, but not with the count of any 
other morphotic element in healthy blood donors. The as-
sociation remains significant after Bonferroni correction for 
multiple testing.
We also evaluated whether a similar association remains 
significant among patients with CAD, admitted for elective 
coronary angiography. The data are presented in Table 4.
The data show that the association observed among 
healthy people is not significant among patients with CAD 
confirmed during elective angiography. The monocyte count is 
not significantly associated with genotypes of rs7023923 poly-
morphism (p = 0.61), and neither is the count of any other 
morphotic element. While erythrocyte count is significantly 
associated with this polymorphism (p = 0.026), correction 
for multiple testing (p = 0.156) abolished this relationship. 
We used logistic regression to correct the results from 
Tables 1 and 3 for age and sex of blood donors and of patients; 
however, this did not modify the significance of the associa-
tions. Our data suggest that factors other than the studied 
polymorphism affect the monocyte count in sick people. 
The influence of genetic factors, determined among healthy 
people, may be less relevant during disease. Factors such as 
patients’ classical risk factors of CAD may be more powerful 
players, and their interaction with genetic effects may dwarf 
in consequence the relevance of the latter.
DISCUSSION
Our analysis confirmed that the previously reported associa-
tion of polymorphism rs7023923 is valid also among healthy 
blood donors in Poland. However, the same association could 
not be demonstrated among patients with CAD, admitted to 
the hospital for elective coronary angiography. This is probably 
due to the fact that environmental factors, coming into play 
in CAD patients, modify the studied association.
An issue of genetic control over clinical parameters is of 
great importance for future diagnostic tests, aimed to stratify 
the population by the risk of developing the specific disease. 
It is quite likely that people with a higher number of mono-
cytes circulating in blood may be prone to develop athero-
sclerosis and its deadly complications, such as MI or stroke. 
The possible underlying mechanism is that the high number 
of circulating monocytes translates into higher numbers of 
Table 3. Association of rs7023923 genotypes with morphotic element counts in blood of healthy donors (n = 69)
Variable Genotypes of rs7023923 P 
CC (n = 33) CT (n = 16) TT (n = 20)
Erythrocytes 4.97 ± 0.45 5.01 ± 0.42 4.86 ± 0.55 0.42
Leukocytes 6.68 ± 1.06 6.39 ± 1.56 6.17 ± 1.17 0.25
Platelets 260.23 ± 66.10 267.78 ± 47.80 282.81 ± 45.91 0.13
Neutrophils 3.65 ± 0.90 3.37 ± 1.39 3.54 ± 0.93 0.18
Lymphocytes 2.16 ± 0.62 2.24 ± 0.49 1.90 ± 0.41 0.12
Monocytes 0.57 ± 0.21 0.41 ± 0.14 0.48 ± 0.12 0.0026
Erythrocytes (mln/μL), other (thousand/μL). P values for Kruskal-Wallis test, comparing count of each morphotic element across the genotype 
strata, uncorrected for multiple testing. Bonferroni corrected p value for monocytes = 0.0156. 
Table 4. Association of rs7023923 genotypes with morphotic element counts in blood of patients with coronary artery disease 
admitted for angioplasty (n = 26)
Variable Genotypes of rs7023923 P 
CC (n = 12) CT (n = 8) TT (n = 6)
Erythrocytes 4.93 ± 0.20 4.61 ± 0.21 5.24 ± 0.11 0.026
Leukocytes 8.73 ± 3.31 8.33 ± 1.10 8.20 ± 1.41 0.98
Platelets 209.50 ± 44.41 203.50 ± 66.93 243.50 ± 21.92 0.44
Neutrophils 5.86 ± 3.21 5.65 ± 0.37 5.35 ± 1.48 0.77
Lymphocytes 2.15 ± 0.42 5.96 ± 7.33 2.15 ± 0.07 0.44
Monocytes 0.57 ± 0.18 0.49 ± 0.15 0.56 ± 0.11 0.61
Mean ± standard deviation values are provided. Erythrocytes (mln/μL), other (thousand/μL). P values for Kruskal-Wallis test, comparing count of 
each morphotic element across the genotype strata, uncorrected for multiple testing. Bonferroni corrected p value for erythrocytes = 0.156.
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monocytes being attracted to the atherosclerotic plaque. In 
this case, increased production of proinflammatory cytokines 
and enhanced presentation of antigens, by the high number 
of monocytes that turn into macrophages, could increase the 
chance of plaque destabilisation and rupture.
Genome wide association studies provided, in the past 
few years, evidence that the majority of complex traits are 
controlled by multiple genetic polymorphisms. Each SNP has 
a rather small impact on the studied trait, in sharp contrast 
to the previously held belief that a handful of polymor-
phisms would exert a potent effect on the studied trait. The 
polymorphism rs7023923 and monocyte count trait are no 
exceptions. Although this association has been replicated 
in several studies, the overall variance in monocyte count, 
controlled by this SNP, is only about 1.5%. A recent study 
demonstrated that this polymorphism upregulates expression 
of the LPAR1 gene [23]. In our opinion, environmental factors, 
some of them hard to measure, e.g. patients’ fear associated 
with the elective procedure of coronary angiography and 
potentially also angioplasty, may exert a much more potent 
effect on monocyte count than the studied polymorphism. 
By definition, risk factors of CAD, e.g. smoking and comor-
bidities such as hypertension or diabetes mellitus, are more 
prevalent among CAD suspects than in healthy people. It is 
not known whether there is any interaction between them 
and polymorphism rs7023923, located near lysophosphatidic 
acid receptor locus. However, such an interaction cannot be 
excluded, since lysophosphatidic acid regulates blood glucose 
concentration [24], accumulates in atherosclerotic lesions, 
and induces smooth muscle cells to produce cytokines [25].
In this situation, the impact of SNP may be overwhelmed 
by the large effect of environmental factors, and therefore not 
detected in a small cohort. We admit that the small number 
of subjects with CAD is a limitation of our study and should 
be remedied by further investigations. Another important 
limitation of our study is the lack of information on the pres-
ence of atherothrombosis risk factors among blood donors 
self-reporting to be healthy. We cannot exclude the possibility 
that a few of these people had subclinical CAD, leading to 
patient misclassification.
CONCLUSIONS
We advise caution when data from the study of quantitative 
phenotypes are directly translated from a cohort of healthy 
people to a hospital-based cohort.
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Polimorfizm rs7023923 i monocytoza u dawców 
krwi oraz pacjentów z chorobą wieńcową
Jarosław Szymon Świrta, Marzena Krzemień-Grandys, Justyna Totoń-Żurańska, Katarzyna Kuś,  
Rafał Olszanecki, Jacek Jawień, Marcin Wnuk, Agnieszka Słowik, Jacek Godlewski,  
Krzysztof Żmudka, Ryszard Korbut, Paweł Piotr Wołkow
Uniwersytet Jagielloński, Collegium Medicum, Kraków
S t r e s z c z e n i e
Wstęp: Istotna rola monocytów w chorobie wieńcowej (CAD) jest dobrze udokumentowana. Wzrost ich liczby w krążeniu 
wiąże się z częstszym występowaniem CAD. Zarówno czynniki środowiskowe, jak i genetyczne wpływają na liczbę mono-
cytów we krwi, te ostatnie zaczęły być poznawane jednak dopiero niedawno, z nadejściem ery badań asocjacyjnych na 
poziomie całego genomu. Kilka takich asocjacji zidentyfikowano u osób zdrowych, pierwsza znaleziona asocjacja dotyczyła 
polimorfizmu rs7023923. Wielkość asocjacji między polimorfizmem a badaną cechą jest często modyfikowana przez czynniki 
środowiskowe i jest różna u chorych w porównaniu ze zdrową populacją. Bardzo ważne jest ustalenie wpływu czynników 
genetycznych właśnie wśród chorych, aby dokładnie przewidzieć efekt choroby, np. zawał serca. 
Cel: Celem badania było stwierdzenie, czy wielkość asocjacji między rs7023923 a liczbą monocytów, uprzednio stwierdzonej 
u osób zdrowych, jest podobna u pacjentów z CAD potwierdzoną podczas planowego zabiegu koronarografii.
Metody i wyniki: Osoby z CAD charakteryzowały się wyższą leukocytozą i neutrofilocytozą, ale niższą trombocytozą w porów-
naniu z osobami zdrowymi. Monocytoza nie różniła się między badanymi grupami (p = 0,25). Potwierdzono istnienie związku 
między rs7023923 a monocytozą u zdrowych dawców krwi (p = 0,0156), lecz nie u pacjentów przyjętych w celu wykonania 
koronarografii (p = 0,61). Uwzględnienie wieku i płci pacjentów w modelu statystycznym nie modyfikowało rezultatów.
Wnioski: Uzyskane wyniki sugerują, że należy zachować dużą ostrożność podczas translacji wyników asocjacji genetycznej 
badanych cech od osób zdrowych do populacji chorych. Jest prawdopodobne, że liczne czynniki środowiskowe, którymi 
różnią się między sobą pacjenci z podejrzeniem CAD od zdrowej populacji, modyfikują stopień asocjacji genetycznej i utrud-
niają jej interpretację.
Słowa kluczowe: monocytoza, polimorfizm, choroba wieńcowa, dawca krwi
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